ClinicalTrials.gg
TerminatedNCT01155986Updated Oct 16, 2019

Lidocaine 5% Medicated Plaster in Chronic Neuropathic Postoperative Pain

A Phase 2 interventional study of Lidocaine 5% medicated plaster and Placebo topical plaster in Pain, Chronic Pain and Neuropathic Pain, sponsored by Grünenthal GmbH. Terminated at 22 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-16.

Sponsored by Grünenthal GmbH · Phase 2, Interventional, and Treatment

Why this study was terminated
Trial was stopped due to difficult enrolment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 204 studies testing lidocaine in Pain — 19 open to participants now, 19 under way, 1 of them phase 3. Lidocaine · Pain.

Enrollment
93rd of 203
74 · median 66
Started
2010
with 16 others
Phase 2
17 of 204
2 open now
Registered
44th of 204
by date

Among the 204 studies testing lidocaine in Pain, this one is the 93rd largest by enrollment of the 203 interventional ones that give a count, is one of 17 that started in 2010, is one of 17 in phase 2, and was the 44th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

19 of the 204 studies testing lidocaine in Pain are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About lidocaine

Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 204 studies testing lidocaine in Pain, or all of them as a file.
02

Study summary

The purpose of this trial is to investigate the efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain in comparison to placebo plaster.

Read the detailed description

Some patients who undergo different types of surgery develop distressing and long-lasting pain. This pain is often characterized by signs such as: allodynia (a pain due to a stimulus which does not normally provoke pain), dysesthesia (unpleasant, abnormal sense of touch). Patients describe symptoms of burning or electrical type sensation. In some cases this type of chronic pain can still be present after 3 months or more following surgery.This clinical trial will assess the efficacy and safety profile of lidocaine 5% medicated plaster in comparison to placebo plaster in patients.

This trial is a randomized, double-blind (neither investigator nor patient will know which treatment was received), placebo-controlled, parallel-group, multicenter trial to evaluate topical analgesic treatment of chronic neuropathic pain after surgery. The trial will include a screening phase and a treatment phase, during which subjects will be treated with either 5% lidocaine medicated plaster, or a placebo plaster pain intensity will be assessed on a daily basis. Subsequently there will be a follow-up phase. Pain intensity numeric rating scale (PI) will be collected via the numeric rating scale and averaged. Safety evaluations include monitoring of adverse events, physical examinations, and clinical laboratory tests.

03

Conditions studied

  • Pain
  • Chronic Pain
  • Neuropathic Pain
  • Postoperative Pain

Keywords

  • analgesic
  • analgesics
  • pain
  • chronic pain
  • localized pain
  • focal pain
  • neuropathic pain
  • postoperative pain
  • topical analgesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects with >= 18 years of age
  • Intact skin in the area of topical treatment
  • Patients suffering from moderate to severe ( 5 or more points on an 11 point Numerical Rating Scale where 10 is the worst possible pain, and 0 indicates no pain) chronic daily postoperative neuropathic pain for the past 6 to 24 months.
  • Patients should have symptoms for example allodynia (a pain due to a stimulus which does not normally provoke pain); and or dysesthesia (unpleasant, abnormal sense of touch).

Exclusion criteria

Exclusion Criteria:

  • to lidocaine 5% medicated plaster, or paracetamol
  • Evidence or history of alcohol, medication or drug abuse and/or dependency in the past 3 years.
  • Evidence or history (during the past 3 years) of epilepsy, neurotic personality, psychiatric illness, or suicide risk.
  • Pregnant or breastfeeding women
  • Women of who are sexually active without satisfactory for at least 28 days prior to enrollment, during the trial, and until 28 days after the follow-up visit.
  • Severe renal, hepatic or heart disorder.
  • Surgery in the past 3 months before screening.
  • Anticipated need for surgery during the trial, requiring at least regional or general anesthesia.
  • Pending litigation due to chronic pain or disability.
  • Participation in another trial of medicinal products or devices parallel to or less than 1 month before entry into the trial, or previous participation in this trial.
  • Presence of other severe pain that could confound the assessment or self- evaluation of the localized postoperative neuropathic pain.
  • For patients with chronic postoperative neuropathic pain related to a surgery due to tumors: suspected residual tumor or , chemotherapy or radiotherapy for treatment of tumor(s).
  • Total anesthesia in the area of localized chronic pain
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
74 participants (actual)

Study arms

  • Placebo comparator
    Placebo Plaster

    Active Comparator

    Drug: Placebo topical plaster

  • Active comparator
    Lidocaine Plaster

    Drug: Lidocaine 5% medicated plaster

Interventions

  • Topical hydrogel plaster (700mg lidocaine)

    Also known as: Versatis(R)

  • DrugPlacebo topical plaster

    Topical hydrogel plaster

06

What researchers measure

Primary outcomes

  1. Analgesic efficacy of lidocaine 5% medicated plaster in comparison to placebo in subjects with moderate to severe localized chronic postoperative neuropathic pain

    Participants will be selected based on their medical history and clinical examination. A questionnaire called DN4, which stands for 'douleur neuropathique 4' (i.e., '4 questions neuropathic pain will be used to identify subjects with neuropathic pain.) Pain will be assessed on and 11-point numerical rating scale (0 = no pain, 10 = worst pain imaginable). Efficacy of the treatment (i.e., reduction of neuropathic pain) will be evaluated with the 11-point numeric rating scale (NRS).

    Time frame: daily assessments over 4 weeks

Secondary outcomes

  1. Effect of lidocaine 5% medicated plaster on quality of life

    EuroQol-5 Dimension Scores

    Time frame: 4 weeks

  2. Neuropathic Pain Symptoms

    Changes in severity of various neuropathic pain symptoms, e.g. allodynia, will be recorded by the Neuropathic Pain Symptom Inventory (NPSI) and neurological examinations

    Time frame: 4 weeks

  3. Incidence of adverse events

    Measurement of adverse events including those derived from laboratory data or vital signs measurements.

    Time frame: up to 44 days

  4. Hospital Anxiety and Depression Scale

    Time frame: 4 weeks

  5. Subject's Global Impression of Change

    Time frame: 4 weeks

  6. Treatment Satisfaction Questionnaire for Medication

    Time frame: 4 weeks

07

Study locations

22 sites
  • Site 31
    Abbeville, France
  • Site 26
    Bayonne, France
  • Site 34
    Bobigny, France
  • Site 35
    Bordeaux, France
  • Site 12
    Boulogne-Billancourt, France
  • Site 24
    Brest, France
  • Site 15
    Chateauroux, France
  • Site 30
    Corbeil Essonnes, France
  • Site 39
    La Roche Sur Yon, France
  • Site 23
    Lille cedex, France
  • Site 17
    Limoges, France
  • Site 21
    Marseille, France
  • Site 33
    Montauban, France
  • Site 14
    Nice Cedex 1, France
  • Site 18
    Orleans, France
  • Site 27
    Paris, France
  • Site 36
    Paris, France
  • Site 22
    Rennes Cedex, France
  • Site 19
    Saint Genis Laval, France
  • Site 20
    Saint-Etienne cedex 2, France
  • Site 38
    Tours, France
  • Site 28
    Voiron, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2010
First posted
Jul 2, 2010
Start
Aug 2010
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Last update
Oct 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01155986
Lead sponsor
Grünenthal GmbH
Responsible party
Sponsor
First posted
Jul 2, 2010
Start date
Aug 2010
Primary completion
Nov 2012
Completion
Nov 2012
Last update
Oct 16, 2019

Study contacts

Jean Bruxelle
principal investigator · Fondation Ophtalmologique Adolphe de Rotschild, Service de Neurochirurgie, CEntre d'Evaluation et de Traitement de la Douleur

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion